NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Oragenics, Inc. OGEN
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-4.56
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-243.9%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 16-year series below
Revenue
Net income
Per share
USD -4.56
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-243.9%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-170.6%
Each USD of equity lost 244 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−28.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 10.1M
total assets, end of FY2025
Total assetsUSD 10.1M
EquityUSD 8.3M
CashUSD 4.4M
Equity funds 82% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
0.0
0.0
0.0
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
−0.0
−0.0
Income tax $B
−0.0
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
·
·
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−4.56
−47.88
−9.18
−7.11
−0.14
−0.47
−0.37
−0.87
−1.37
−1.57
−0.32
−0.16
−0.56
−0.74
−1.34
−1.42
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−243.9
−714.9
−255.4
−72.4
−72.5
−155.1
−81.7
−72.9
−145.0
−182.2
−155.5
−44.2
−128.2
−2487.9
·
·
Shares out B
0.00
0.00
0.00
0.00
0.00
0.09
0.05
0.03
0.00
0.00
0.04
0.04
0.04
0.03
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
53 of 53
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed